Prognostic Implication of 15-Hydroxyprostaglandin Dehydrogenase Down-Regulation in Patients with Colorectal Cancer.
10.3393/jksc.2012.28.5.253
- Author:
Pil Sung KANG
1
;
Jin Ha KIM
;
Ok In MOON
;
Sung Chul LIM
;
Kyung Jong KIM
Author Information
1. Department of Surgery, Chosun University School of Medicine, Gwangju, Korea. kjkim@chosun.ac.kr
- Publication Type:Original Article
- Keywords:
Colorectal neoplasms;
15-hydroxyprostaglandin dehydrogenase;
Down-regulation;
Immunohistochemistry;
Prognosis
- MeSH:
Carcinoembryonic Antigen;
Colorectal Neoplasms;
Down-Regulation;
Humans;
Hydroxyprostaglandin Dehydrogenases;
Immunohistochemistry;
Lymph Nodes;
Neoplasm Metastasis;
Oxidoreductases;
Prognosis;
Survival Rate
- From:Journal of the Korean Society of Coloproctology
2012;28(5):253-258
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Prostaglandin (PG) E2 is known to be closely related to cancer progression and is inactivated by 15-hydroxyprostaglandin dehydrogenase (PGDH). 15-PGDH is shown to have tumor suppressor activity and to be down-regulated in various cancers, including colorectal cancer (CRC). Therefore, we evaluated the expression of 15-PGDH and its prognostic effect in patients with CRC. METHODS: 15-PGDH expression was examined by using immunohistochemistry in 77 patients with CRC. Its prognostic significance was statistically evaluated. RESULTS: Negative 15-PGDH expression was noted in 55.8% of the 77 cases of CRC. 15-PGDH expression showed no correlation with any of the various clinicopathologic parameters. The status of lymph node metastasis, tumor-node-metastasis stages, and pre-operative carcinoembryonic antigen levels showed significant prognostic effect. However, univariate analysis revealed down-regulation of 15-PGDH not to be a predictor of poor survival. The 5-year overall survival rate was 71.7% in the group with positive expression of 15-PGDH and 67.1% in the group with negative expression of 15-PGDH, but this difference was not statistically significant (P = 0.751). CONCLUSION: 15-PGDH was down-regulated in 55.8% of the colorectal cancer patients. However, down-regulation of 15-PGDH showed no prognostic value in patients with CRC. Further larger scale or prospective studies are needed to clarify the prognostic effect of 15-PGDH down-regulation in patients with colorectal cancer.
